 Gregory Forlenza
Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Infusion Systems | 86 | 2025 | 394 | 17.660 |
Why?
| | Diabetes Mellitus, Type 1 | 109 | 2025 | 3715 | 12.590 |
Why?
| | Blood Glucose Self-Monitoring | 76 | 2025 | 641 | 9.380 |
Why?
| | Pancreas, Artificial | 31 | 2025 | 84 | 9.340 |
Why?
| | Insulin | 88 | 2025 | 2409 | 9.120 |
Why?
| | Hypoglycemic Agents | 85 | 2025 | 1291 | 9.060 |
Why?
| | Blood Glucose | 99 | 2025 | 2186 | 8.820 |
Why?
| | Hypoglycemia | 33 | 2025 | 445 | 5.850 |
Why?
| | Hyperglycemia | 15 | 2023 | 347 | 3.310 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2022 | 622 | 2.110 |
Why?
| | Diabetes Mellitus | 10 | 2025 | 1040 | 1.800 |
Why?
| | Islets of Langerhans Transplantation | 5 | 2024 | 64 | 1.730 |
Why?
| | Monitoring, Ambulatory | 5 | 2018 | 87 | 1.700 |
Why?
| | Child | 64 | 2025 | 21935 | 1.530 |
Why?
| | Pancreatectomy | 5 | 2024 | 253 | 1.500 |
Why?
| | Adolescent | 63 | 2025 | 21513 | 1.470 |
Why?
| | Algorithms | 18 | 2025 | 1704 | 1.460 |
Why?
| | Humans | 140 | 2025 | 137585 | 1.350 |
Why?
| | Insulin-Secreting Cells | 3 | 2023 | 377 | 1.320 |
Why?
| | Pancreatitis, Chronic | 4 | 2024 | 58 | 1.220 |
Why?
| | Biomedical Technology | 2 | 2019 | 43 | 1.170 |
Why?
| | Young Adult | 36 | 2025 | 13209 | 1.110 |
Why?
| | Verapamil | 2 | 2023 | 41 | 1.040 |
Why?
| | Patient Education as Topic | 3 | 2021 | 766 | 1.020 |
Why?
| | Adult | 51 | 2025 | 37929 | 0.890 |
Why?
| | Male | 60 | 2025 | 67762 | 0.840 |
Why?
| | Telemedicine | 3 | 2022 | 862 | 0.830 |
Why?
| | Technology | 5 | 2023 | 96 | 0.820 |
Why?
| | Caregivers | 3 | 2025 | 877 | 0.800 |
Why?
| | Calcium Channel Blockers | 1 | 2023 | 167 | 0.770 |
Why?
| | Female | 58 | 2025 | 73304 | 0.760 |
Why?
| | Child, Preschool | 19 | 2025 | 11074 | 0.740 |
Why?
| | Lymphoma | 1 | 2023 | 208 | 0.720 |
Why?
| | Glucose | 9 | 2024 | 1020 | 0.690 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2025 | 2531 | 0.660 |
Why?
| | Patient Dropouts | 1 | 2020 | 67 | 0.630 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 289 | 0.620 |
Why?
| | Treatment Outcome | 18 | 2025 | 10811 | 0.610 |
Why?
| | Patient Satisfaction | 3 | 2024 | 660 | 0.610 |
Why?
| | Personal Satisfaction | 1 | 2020 | 207 | 0.590 |
Why?
| | Diabetic Ketoacidosis | 5 | 2024 | 201 | 0.580 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 170 | 0.560 |
Why?
| | Eczema | 1 | 2018 | 69 | 0.550 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.530 |
Why?
| | Diabetic Retinopathy | 2 | 2024 | 189 | 0.520 |
Why?
| | Self-Management | 1 | 2019 | 176 | 0.520 |
Why?
| | Diffusion of Innovation | 1 | 2017 | 99 | 0.510 |
Why?
| | Machine Learning | 2 | 2025 | 493 | 0.500 |
Why?
| | Artificial Intelligence | 1 | 2019 | 279 | 0.480 |
Why?
| | Quality of Life | 4 | 2024 | 2892 | 0.480 |
Why?
| | Insulin, Regular, Human | 7 | 2023 | 43 | 0.470 |
Why?
| | Endocrine Glands | 1 | 2015 | 15 | 0.470 |
Why?
| | Transplantation, Autologous | 4 | 2024 | 238 | 0.470 |
Why?
| | Insulin Lispro | 3 | 2024 | 39 | 0.460 |
Why?
| | Endocrine System Diseases | 1 | 2015 | 35 | 0.460 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.460 |
Why?
| | C-Peptide | 3 | 2025 | 163 | 0.460 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.460 |
Why?
| | Fanconi Anemia | 1 | 2013 | 11 | 0.430 |
Why?
| | Dwarfism | 1 | 2013 | 17 | 0.430 |
Why?
| | Growth Hormone | 1 | 2013 | 101 | 0.420 |
Why?
| | Skin | 1 | 2018 | 752 | 0.410 |
Why?
| | Retrospective Studies | 12 | 2024 | 15657 | 0.410 |
Why?
| | Aged | 19 | 2024 | 23961 | 0.400 |
Why?
| | Blindness | 1 | 2012 | 38 | 0.390 |
Why?
| | Suicide | 1 | 2020 | 656 | 0.390 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 812 | 0.370 |
Why?
| | Cross-Over Studies | 6 | 2024 | 564 | 0.370 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 539 | 0.360 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.360 |
Why?
| | Middle Aged | 22 | 2025 | 33479 | 0.350 |
Why?
| | Exercise | 8 | 2025 | 2057 | 0.350 |
Why?
| | Angiogenesis Inhibitors | 1 | 2012 | 229 | 0.350 |
Why?
| | Biosensing Techniques | 2 | 2025 | 129 | 0.350 |
Why?
| | Calibration | 3 | 2020 | 146 | 0.340 |
Why?
| | Lingual Frenum | 1 | 2010 | 2 | 0.340 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1477 | 0.340 |
Why?
| | Tongue Diseases | 1 | 2010 | 9 | 0.340 |
Why?
| | Failure to Thrive | 1 | 2010 | 29 | 0.330 |
Why?
| | United States | 13 | 2025 | 14841 | 0.330 |
Why?
| | Epidemics | 1 | 2011 | 89 | 0.330 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 2111 | 0.330 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 545 | 0.320 |
Why?
| | Medicaid | 3 | 2022 | 435 | 0.320 |
Why?
| | Models, Biological | 1 | 2016 | 1783 | 0.310 |
Why?
| | Double-Blind Method | 4 | 2023 | 1993 | 0.300 |
Why?
| | Infant | 6 | 2023 | 9465 | 0.300 |
Why?
| | Skiing | 2 | 2019 | 47 | 0.280 |
Why?
| | Follow-Up Studies | 5 | 2021 | 5131 | 0.280 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 2 | 2017 | 27 | 0.270 |
Why?
| | Prospective Studies | 7 | 2025 | 7604 | 0.270 |
Why?
| | Inventions | 2 | 2018 | 20 | 0.270 |
Why?
| | Endocrinology | 2 | 2018 | 79 | 0.250 |
Why?
| | Insulin Aspart | 2 | 2022 | 27 | 0.240 |
Why?
| | Meals | 4 | 2024 | 125 | 0.240 |
Why?
| | Outpatients | 2 | 2021 | 396 | 0.240 |
Why?
| | Overweight | 2 | 2023 | 558 | 0.240 |
Why?
| | Postoperative Complications | 2 | 2015 | 2654 | 0.240 |
Why?
| | Injections, Subcutaneous | 3 | 2020 | 157 | 0.230 |
Why?
| | Risk Factors | 5 | 2020 | 10388 | 0.230 |
Why?
| | Body Height | 2 | 2017 | 199 | 0.220 |
Why?
| | Mutation | 1 | 2015 | 3958 | 0.210 |
Why?
| | Feasibility Studies | 5 | 2018 | 956 | 0.210 |
Why?
| | Equipment Failure | 3 | 2018 | 108 | 0.190 |
Why?
| | Insulins | 1 | 2023 | 37 | 0.190 |
Why?
| | Eligibility Determination | 1 | 2022 | 65 | 0.190 |
Why?
| | Awareness | 1 | 2023 | 103 | 0.190 |
Why?
| | Pediatrics | 2 | 2020 | 1101 | 0.180 |
Why?
| | Automobile Driving | 1 | 2023 | 148 | 0.170 |
Why?
| | Infusion Pumps, Implantable | 1 | 2020 | 25 | 0.170 |
Why?
| | Computer Systems | 1 | 2020 | 45 | 0.160 |
Why?
| | Smartphone | 2 | 2019 | 91 | 0.160 |
Why?
| | Medicare | 2 | 2022 | 773 | 0.160 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2019 | 63 | 0.160 |
Why?
| | Fatal Outcome | 1 | 2020 | 303 | 0.150 |
Why?
| | Sports | 2 | 2019 | 231 | 0.150 |
Why?
| | Reproducibility of Results | 4 | 2024 | 3284 | 0.150 |
Why?
| | Prevalence | 3 | 2023 | 2734 | 0.150 |
Why?
| | Software | 2 | 2021 | 665 | 0.140 |
Why?
| | Clinical Alarms | 1 | 2017 | 10 | 0.140 |
Why?
| | Night Terrors | 1 | 2017 | 1 | 0.140 |
Why?
| | Insulinoma | 1 | 2017 | 26 | 0.140 |
Why?
| | Device Approval | 1 | 2017 | 21 | 0.140 |
Why?
| | Diet, Diabetic | 1 | 2017 | 34 | 0.130 |
Why?
| | Survival Analysis | 1 | 2020 | 1325 | 0.130 |
Why?
| | Voluntary Health Agencies | 1 | 2016 | 5 | 0.130 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2017 | 37 | 0.130 |
Why?
| | Program Evaluation | 1 | 2021 | 898 | 0.130 |
Why?
| | Obesity | 3 | 2023 | 2992 | 0.130 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 208 | 0.120 |
Why?
| | Pancreaticoduodenectomy | 1 | 2017 | 164 | 0.120 |
Why?
| | Statistics as Topic | 1 | 2016 | 307 | 0.120 |
Why?
| | Abdominal Pain | 1 | 2017 | 145 | 0.120 |
Why?
| | Hypophosphatasia | 1 | 2015 | 3 | 0.120 |
Why?
| | Drug Overdose | 1 | 2020 | 347 | 0.120 |
Why?
| | Age Factors | 3 | 2018 | 3295 | 0.120 |
Why?
| | Automation | 2 | 2025 | 95 | 0.120 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 365 | 0.120 |
Why?
| | Health Services Accessibility | 1 | 2022 | 986 | 0.120 |
Why?
| | Pilot Projects | 2 | 2020 | 1710 | 0.110 |
Why?
| | Alkaline Phosphatase | 1 | 2015 | 148 | 0.110 |
Why?
| | Autografts | 1 | 2014 | 44 | 0.110 |
Why?
| | History, 21st Century | 2 | 2025 | 213 | 0.110 |
Why?
| | Consensus | 3 | 2023 | 683 | 0.110 |
Why?
| | History, 20th Century | 2 | 2025 | 325 | 0.110 |
Why?
| | Europe | 2 | 2025 | 414 | 0.110 |
Why?
| | Choristoma | 1 | 2013 | 21 | 0.110 |
Why?
| | Glucose Clamp Technique | 1 | 2014 | 195 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 322 | 0.110 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2013 | 38 | 0.100 |
Why?
| | Infusions, Intravenous | 1 | 2014 | 413 | 0.100 |
Why?
| | Postoperative Period | 1 | 2014 | 342 | 0.100 |
Why?
| | Pituitary Gland | 1 | 2013 | 148 | 0.100 |
Why?
| | Allografts | 1 | 2013 | 146 | 0.100 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5778 | 0.100 |
Why?
| | Graft Survival | 1 | 2015 | 535 | 0.100 |
Why?
| | Patient Compliance | 1 | 2017 | 581 | 0.100 |
Why?
| | Bionics | 2 | 2022 | 12 | 0.100 |
Why?
| | Clinical Protocols | 1 | 2014 | 271 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1178 | 0.100 |
Why?
| | Genetic Testing | 1 | 2015 | 460 | 0.090 |
Why?
| | Adolescent Behavior | 1 | 2017 | 530 | 0.090 |
Why?
| | Pituitary Neoplasms | 1 | 2013 | 190 | 0.090 |
Why?
| | Graft Rejection | 1 | 2015 | 624 | 0.090 |
Why?
| | Adipose Tissue | 1 | 2016 | 635 | 0.090 |
Why?
| | Body Mass Index | 2 | 2017 | 2389 | 0.090 |
Why?
| | Prognosis | 2 | 2020 | 4030 | 0.090 |
Why?
| | Age of Onset | 1 | 2012 | 518 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2844 | 0.080 |
Why?
| | Biomedical Research | 1 | 2016 | 692 | 0.080 |
Why?
| | Critical Illness | 1 | 2016 | 811 | 0.080 |
Why?
| | Activities of Daily Living | 3 | 2017 | 413 | 0.080 |
Why?
| | Global Health | 1 | 2012 | 386 | 0.080 |
Why?
| | Pancreatic Neoplasms | 1 | 2017 | 938 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2016 | 1069 | 0.080 |
Why?
| | Biomarkers | 1 | 2020 | 4149 | 0.070 |
Why?
| | Guideline Adherence | 1 | 2012 | 556 | 0.070 |
Why?
| | Hospitalization | 3 | 2024 | 2199 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2015 | 3556 | 0.070 |
Why?
| | Equipment Design | 2 | 2019 | 522 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2019 | 6079 | 0.070 |
Why?
| | Cold Temperature | 2 | 2019 | 179 | 0.070 |
Why?
| | Weight Gain | 1 | 2010 | 519 | 0.060 |
Why?
| | Breast Feeding | 1 | 2010 | 440 | 0.060 |
Why?
| | Time Factors | 3 | 2025 | 6828 | 0.060 |
Why?
| | Incidence | 1 | 2012 | 2804 | 0.060 |
Why?
| | Seasons | 2 | 2019 | 547 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 1587 | 0.060 |
Why?
| | Risk | 2 | 2017 | 912 | 0.060 |
Why?
| | Child Abuse | 1 | 2010 | 535 | 0.050 |
Why?
| | Mass Screening | 1 | 2012 | 1287 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1236 | 0.050 |
Why?
| | Diet | 1 | 2011 | 1278 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2025 | 405 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2023 | 113 | 0.050 |
Why?
| | Insulin Resistance | 1 | 2011 | 1208 | 0.050 |
Why?
| | Standard of Care | 1 | 2023 | 72 | 0.050 |
Why?
| | Pregnancy | 2 | 2025 | 6763 | 0.050 |
Why?
| | Reference Standards | 1 | 2021 | 186 | 0.040 |
Why?
| | Insurance Coverage | 1 | 2022 | 230 | 0.040 |
Why?
| | Cohort Studies | 2 | 2025 | 5742 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2020 | 73 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2023 | 591 | 0.040 |
Why?
| | Pancreas | 1 | 2022 | 329 | 0.040 |
Why?
| | Social Conditions | 1 | 2019 | 12 | 0.040 |
Why?
| | Inpatients | 1 | 2024 | 500 | 0.040 |
Why?
| | Disease Management | 1 | 2023 | 628 | 0.040 |
Why?
| | Health Personnel | 1 | 2025 | 710 | 0.040 |
Why?
| | Equipment and Supplies | 1 | 2018 | 42 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 198 | 0.040 |
Why?
| | Postprandial Period | 1 | 2018 | 107 | 0.030 |
Why?
| | Virginia | 1 | 2017 | 62 | 0.030 |
Why?
| | Snacks | 1 | 2017 | 19 | 0.030 |
Why?
| | Colorado | 2 | 2017 | 4565 | 0.030 |
Why?
| | Ohio | 1 | 2017 | 152 | 0.030 |
Why?
| | Mobile Applications | 1 | 2020 | 183 | 0.030 |
Why?
| | Reference Values | 1 | 2018 | 816 | 0.030 |
Why?
| | Minnesota | 1 | 2017 | 164 | 0.030 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 108 | 0.030 |
Why?
| | Accelerometry | 1 | 2017 | 103 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 282 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2022 | 654 | 0.030 |
Why?
| | Food Preferences | 1 | 2017 | 119 | 0.030 |
Why?
| | Hypertrophy | 1 | 2016 | 133 | 0.030 |
Why?
| | Materials Testing | 1 | 2017 | 356 | 0.030 |
Why?
| | Child Behavior | 1 | 2017 | 248 | 0.030 |
Why?
| | Pain Measurement | 1 | 2017 | 521 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 820 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 654 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2022 | 7635 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1313 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2828 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3566 | 0.010 |
Why?
|
|
Forlenza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|